Zimmer Biomet Receives FDA Clearance for OsseoFit Stemless Shoulder System for Total Shoulder Replacement
Zimmer Biomet Receives FDA Clearance for OsseoFit Stemless Shoulder System for Total Shoulder Replacement
New Anatomically Shaped Asymmetric Stemless Design for Total Shoulder Replacement
新的人体解剖形状不对称无杆设计,用于全肩关节置换
WARSAW, Ind., Dec. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the OsseoFit Stemless Shoulder System for total shoulder replacement. This innovative implant is designed to match the natural humeral (upper shoulder bone) anatomy1-3 to optimize anatomical fit while maximizing preservation of healthy bone. The OsseoFit Stemless Shoulder System expands the company's expansive total shoulder portfolio and integrates with Identity Humeral Heads with Versa-Dial Technology for infinite offset placement as well as the Alliance Glenoid for a broad range of glenoid options to adapt to a patient's unique anatomy.
美国印第安纳州华沙,2024年12月13日 /PRNewswire/ -- 齐默巴奥米特控股公司(纽交所和瑞士证券交易所:ZBH),全球领先的医疗科技公司,今天宣布获得美国食品和药物管理局(FDA)510(k)批准,用于全肩关节置换的OsseoFit无杆肩关节系统。这款创新的植入物旨在与自然的肱骨(上肩骨)解剖结构相匹配,以优化解剖适应性,同时最大限度地保留健康骨骼。OsseoFit无杆肩关节系统扩展了公司广泛的全肩关节产品组合,并可与Identity肱骨头和Versa-Dial科技集成,实现无限偏移放置,以及与Alliance盂配合,提供广泛的盂部选项,以适应患者独特的解剖结构。
"The OsseoFit Stemless Shoulder System combines an anatomically shaped implant1-3 which supports bone conservation and is designed for stable initial fixation4-7, with our proprietary OsseoTi Porous Metal Technology for biological fixation,"8,9* said Brian Hatcher, President, SET & CMFT at Zimmer Biomet. "We are pleased to offer OsseoFit within our robust shoulder portfolio that includes modular, compatible components which provide surgeons with a multitude of options based on patients' unique anatomy while maintaining a small instrument footprint and maximizing workflow efficiency."
齐默巴奥米特的总裁布赖恩·哈切尔(Brian Hatcher)表示:“OsseoFit无杆肩关节系统结合了具有解剖形状的植入物,支持骨骼保护,并设计用于稳定的初始固定,与我们专有的OsseoTi多孔金属科技结合,促进生物固定。”我们很高兴能在我们强大的肩关节产品组合中提供OsseoFit,其中包括模块化、兼容的元件,为外科医生提供基于患者独特解剖结构的多种选择,同时保持小型器械占位,并最大化工作流程效率。
The anatomically designed left- or-right-sided anchor implants feature fins which create a press-fit during insertion and contain fully porous windows. The fin geometry and anchor spacing of the implant determine proper orientation and fit1-3 into the natural bone and help avoid cortical impingement, while reaching dense bone areas.2,3,10 In addition, the design includes strategically located anterior reattachment suture holes on the anchor to facilitate subscapularis repair. The system is available in a singular instrument tray to maximize workflow, and sterile process efficiency, to fit nicely in a variety of settings including ambulatory surgical centers.
这种解剖设计的左右侧锚植入物具有在插入过程中产生压紧配合的鳍,并包含完全多孔的窗口。植入物的鳍几何形状和锚间距判断正确的方向和适合程度,以适应自然骨骼并帮助避免皮质挤压,同时到达稠密骨区。此外,设计中包括位于锚上的前部缝合孔,以促进肩胛下肌的修复。该系统提供在一个仪器托盘中,最大化工作流程和无菌过程效率,适合包括门诊手术中心在内的多种环境。
"As younger and more active patients require shoulder replacements, bone preservation becomes increasingly critical to accommodate potential revision procedures in the future," said John W. Sperling, MD, MBA, Professor of Orthopedic Surgery at Mayo Clinic, and a member of the OsseoFit Stemless Shoulder System surgeon development team. "Using a method that mimics the asymmetry of the natural humerus enables surgeons to preserve native bone while optimizing fixation."
“随着年轻和更活跃的患者需要肩关节置换,骨骼的保护变得愈加重要,以适应未来潜在的修复程序,”梅奥诊所骨科手术教授、OsseoFit无杆肩关节系统外科医生开发团队成员约翰·W·斯佩林(John W. Sperling)医学博士、工商管理硕士说。“采用一种模仿自然肱骨不对称的方法,使外科医生能够在优化固定的同时保留原生骨。”
The OsseoFit Stemless Shoulder will be commercially available in Q1 2025.
OsseoFit无杆肩关节将在2025年第一季度商业推出。
Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
梅奥诊所在本新闻稿中提到的科技方面有经济利益。梅奥诊所将利用其所获得的营业收入支持其非营利使命,包括患者护理、教育和研究。
About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
关于齐默巴奥米特控股
齐默巴奥米特控股是全球医疗科技领导者,拥有全面的产品组合,旨在最大化移动性并改善健康。我们通过创新产品和一整套集成的数字化及机器人科技在患者体验上实现无缝转变,这些科技利用数据、数据分析和人工智能。
With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.
凭借90多年值得信赖的领导地位和证明的专业知识,齐默巴奥米特控股在为患者和提供者提供最高质量解决方案方面处于领先地位。我们的遗产通过不断进步的文化和创新精神在今天继续延续。
For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit or follow on LinkedIn at or X / Twitter at .
有关我们产品组合的信息、我们在25多个国家的运营和在100多个国家的销售,或关于加入我们团队的详细信息,请访问或在LinkedIn上关注,或在X / Twitter上关注。
Cautionary Statement Regarding Forward-Looking Statements
关于前瞻性声明的警示声明
This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.
本新闻发布包含1995年《私人证券诉讼改革法》的安全港条款所指的前瞻性陈述。前瞻性陈述包括但不限于有关齐默巴奥米特的期望、计划、前景以及产品和服务提供的声明,包括新产品发布和潜在的临床成功。这些陈述基于管理层当前的信念和期望,并受到重大风险、不确定性和情况变化的影响,这可能导致实际结果与预期有重大差异。有关某些此类风险和不确定性的列表及描述,请参见齐默巴奥米特向美国证券交易委员会(SEC)提交的定期报告。这些因素不应被解释为详尽的,并应与齐默巴奥米特在SEC提交的其他警示性声明一起阅读。前瞻性陈述仅在作出之日有效,齐默巴奥米特免责声明对任何前瞻性陈述进行更新或修订的意图或义务,无论是由于新信息、未来事件或其他原因。本新闻发布的读者被警告不要依赖这些前瞻性陈述,因为不能保证这些前瞻性陈述将被证明是准确的。此警示声明适用于本新闻发布中包含的所有前瞻性陈述。
References
参考文献
*Animal Studies are not necessarily indicative of clinical performance.
*动物研究不一定能反映临床表现。
- Mueri, C., Snethen, K., Parisi, R., Son, Yang., Duquin, T. Characterization of the Asymmetric Bone Envelope of the Proximal Humeral Metaphysis for Stemless Shoulder Implants. Accepted for presentation at the ORS Orthopaedic Research Society 2025 Annual Meeting; 2025 Feb 7-11; Phoenix, Arizona.
- Son, Y, Mueri, C., Snethen, K., Bowman, L., Parisi, R., Duquin, T. Optimizing Stemless Humeral Anchors: Asymmetrical Designs for Minimizing Cortical Bone Impingement while Maximizing Cancellous Bone Purchase. Accepted for presentation at the ORS Orthopaedic Research Society 2025 Annual Meeting; 2025 Feb 7-11; Phoenix, Arizona.
- ZRR_WI_6743_24. Zimmer Biomet Internal Research Report on File.
- Snethen, K., Mueri, C., Kriska, T., Son, Y., Bandi, M. The Sensitivity of the Stability of Stemless Humeral Implants to Surgical, Patient and Design Factors in Reverse Shoulder Arthroplasty. Presented at the ORS Orthopaedic Research Society Annual Meeting; 2023, Dallas, Texas.
- Snethen, K., Son, Y., Mueri, C., Bischoff, J. The Effect of Press-fit on Initial Stability in Stemless Shoulder Arthroplasty. Presented at the ISTA International Society for Technology in Arthroplasty Annual Meeting; 2022, Maui, Hawaii.
- Snethen, K., Mueri, C., Son, Y., Parisi, R., Duquin, T. The Effect of Geometric Design on Initial Stability of Stemless. Accepted for presentation at the ORS Orthopaedic Research Society 2025 Annual Meeting; 2025 Feb 7-11; Phoenix, Arizona.
- ZBTR_30118. Zimmer Biomet Internal Research Report on File.
- OsseoTi Porous Metal Technology uses anatomical data in combination with 3D printing technology to build a structure designed to mimic the architecture of human cancellous – or spongey - bone.
- Gupta, G. Evaluation of Bony Ingrowth Implant Materials in an In Vivo Sheep Long Bone Defect Model 12-04/12-07, February 2013. 32.
- Hamidreza Alidousti, Joshua W Giles, Roger J H Emery, Jonathan Jeffers, Spatial mapping of humeral head bone density, Journal of Shoulder and Elbow Surgery 2017, Vol 26, 1653-1661.
- Mueri, C., Snethen万., Parisi, R., Son, Yang., Duquin万亿。对无干扰肩关节植入物近端肱骨干骺的非对称骨包络特征进行研究。已接受在2025年ORS骨科研究学会年会上展示;2025年2月7-11日;亚利桑那州凤凰城。
- Son, Y, Mueri, C., Snethen万., Bowman, L., Parisi, R., Duquin万亿。优化无干扰肱骨锚:减少皮质骨干扰并最大化松质骨购买的非对称设计。已接受在2025年ORS骨科研究学会年会上展示;2025年2月7-11日;亚利桑那州凤凰城。
- ZRR_WI_6743_24. 齐默巴奥米特内部研究报告存档。
- Snethen万., Mueri, C., Kriska万亿., Son, Y., Bandi万. 在逆向肩关节置换术中,无干预肱骨植入物稳定性的敏感性与外科、患者及设计因素的关系。于2023年在德克萨斯州达拉斯举办的ORS骨科研究学会年会上发布。
- Snethen万., Son, Y., Mueri, C., Bischoff, J. 压制贴合对无干预肩关节置换术初始稳定性的影响。于2022年在夏威夷毛伊岛举办的ISTA国际关节置换技术学会年会上发布。
- Snethen万., Mueri, C., Son, Y., Parisi, R., Duquin万亿. 几何设计对无干预植入物初始稳定性的影响。已被接受在2025年ORS骨科研究学会年会上发布;2025年2月7-11日;亚利桑那州凤凰城。
- ZBTR_30118. 齐默巴奥米特内部研究报告存档。
- OsseoTi多孔金属技术结合解剖数据与3D打印技术,构建出旨在模仿人类松质骨结构的设计。
- Gupta, G. 对羊长骨缺损模型中骨生长植入材料的评估 12-04/12-07, 2013年2月。32。
- Hamidreza Alidousti, Joshua W Giles, Roger J H Emery, Jonathan Jeffers, 肱骨头骨密度的空间映射,《肩肘外科杂志》2017年,卷26,1653-1661。
Media |
Investors |
|
Heather Zoumas-Lubeski |
David DeMartino 646-531-6115 [email protected] |
|
Kirsten Fallon 781-779-5561 |
Zach Weiner [email protected] |
媒体 |
投资者 |
|
希瑟·佐马斯-卢贝斯基 |
大卫·德马蒂诺 646-531-6115 [email protected] |
|
基尔斯滕·法伦 781-779-5561 |
扎克·维纳 [email protected] |
SOURCE Zimmer Biomet Holdings, Inc.
信息来源:齐默巴奥米特控股公司。